Evidence map›Paper›PMID 35482905›Full record

ArticlemAbs

Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering.

Yuji Hori, Ken Ohmine, Hitoshi Katada, Yuki Noguchi, Kazuki Sato, Takeru Nambu, Lam Runyi Adeline, Gan Siok Wan, Kenta Haraya, Kazuhisa Ozeki and 7 more

Open access · goldAbstract read
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yuji HoriResearch Division, Chugai Pharmaceutical Co, Ltd, Gotemba, Japan.
Ken OhmineResearch Division, Chugai Pharmaceutical Co, Ltd, Gotemba, Japan.
Hitoshi KatadaChugai Pharmabody Research Pte. Ltd, Singapore.
Yuki NoguchiResearch Division, Chugai Pharmaceutical Co, Ltd, Gotemba, Japan.
Kazuki SatoResearch Division, Chugai Pharmaceutical Co, Ltd, Gotemba, Japan.
Takeru NambuChugai Pharmabody Research Pte. Ltd, Singapore.
Lam Runyi AdelineChugai Pharmabody Research Pte. Ltd, Singapore.
Gan Siok WanChugai Pharmabody Research Pte. Ltd, Singapore.ORCID 0000-0002-6982-4492
Kenta HarayaResearch Division, Chugai Pharmaceutical Co, Ltd, Gotemba, Japan.
Kazuhisa OzekiResearch Division, Chugai Pharmaceutical Co, Ltd, Gotemba, Japan.
Masahiko NanamiResearch Division, Chugai Pharmaceutical Co, Ltd, Gotemba, Japan.
Tatsuhiko TachibanaResearch Division, Chugai Pharmaceutical Co, Ltd, Gotemba, Japan.
Zenjiro SampeiResearch Division, Chugai Pharmaceutical Co, Ltd, Gotemba, Japan.
Taichi KuramochiResearch Division, Chugai Pharmaceutical Co, Ltd, Gotemba, Japan.ORCID 0000-0001-7242-7124
Junichi NezuResearch Division, Chugai Pharmaceutical Co, Ltd, Chuo-ku, Tokyo, Japan.
Kunihiro HattoriResearch Division, Chugai Pharmaceutical Co, Ltd, Kamakura, Japan.
Tomoyuki IgawaResearch Division, Chugai Pharmaceutical Co, Ltd, Chuo-ku, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A conventional antibody targeting a soluble antigen in circulation typically requires a huge dosage and frequent intravenous administration to neutralize the antigen. This is because antigen degradation is reduced by the formation of antigen-antibody immune complexes, which escape from lysosomal degradation using neonatal Fc receptor (FcRn)-mediated recycling. To address this, we developed an antigen-sweeping antibody that combines pH-dependent antigen binding and Fc engineering to enhance Fc receptor binding. The sweeping antibody actively eliminates the plasma antigens by increasing the cellular uptake of the immune complex and dissociating the antigens in the acidic endosome for degradation. Strong antigen sweeping can reduce the dosage, potentially achieve higher efficacy, and expand the scope of antigen space available for targeting by antibodies. In this study, to further improve the sweeping efficacy, we developed a novel antibody Fc variant by enhancing Fcγ receptor IIb (FcγRIIb) binding and modulating charge characteristics for increased cellular uptake of the immune complex, together with enhancing FcRn binding for efficient salvage of the antigen-free antibodies. Our Fc variant achieved strong antigen sweeping in cynomolgus monkeys with antibody pharmacokinetics comparable to a wild-type human IgG

Indexed as

Antigen-Antibody ComplexAntigensAnimalsHumansHydrogen-Ion ConcentrationImmunoglobulin Fc FragmentsMacaca fascicularisAntigen-Antibody ComplexAntigensImmunoglobulin Fc Fragmentsantibody engineeringcharge engineeringcynomolgus monkey cross-reactiveFc engineeringFcγRIIbpH-dependent antigen-binding antibodysweeping antibodyWord

Identifiers

PMID35482905
PMCPMC9067469
OpenAlexW4225010511

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.